Last $4.06 USD
Change Today -0.31 / -7.09%
Volume 188.3K
TROV On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
NASDAQ CM
As of 8:10 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

trovagene inc (TROV) Snapshot

Open
$4.54
Previous Close
$4.37
Day High
$4.58
Day Low
$3.96
52 Week High
08/29/13 - $9.14
52 Week Low
08/1/14 - $2.97
Market Cap
76.7M
Average Volume 10 Days
254.4K
EPS TTM
$-0.59
Shares Outstanding
18.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TROVAGENE INC (TROV)

trovagene inc (TROV) Related Bloomberg News

View More Bloomberg News

trovagene inc (TROV) Related Businessweek News

No Related Businessweek News Found

trovagene inc (TROV) Details

Trovagene, Inc., a development stage molecular diagnostic company, focuses on the development and commercialization of a proprietary urine-based molecular diagnostic technology. Its technology is used in the detection and monitoring of diseases in various medical disciplines, primarily the management of cancer treatment. The company’s proprietary urine-based molecular diagnostic tests are used to detect cell-free DNA and RNA originating from normal and diseased cell death that can be isolated and detected from urine. Its technology is applied in various testing, such as tumor mutation detection and monitoring, infectious disease monitoring, transplantation monitoring, and prenatal genetic diagnostics. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

25 Employees
Last Reported Date: 08/7/14
Founded in 1999

trovagene inc (TROV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $533.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $333.8K
Chief Scientific Officer
Total Annual Compensation: $269.7K
Compensation as of Fiscal Year 2013.

trovagene inc (TROV) Key Developments

Trovagene Provides Update on its Urine-Based HPV Test

Trovagene, Inc. announced that results from two clinical studies will be presented at the 29th International Papillomavirus (IPV) conference for the company's urine-based diagnostic test for the detection of high risk strains of Human Papillomavirus (HPV). The IPV conference is scheduled to take place in Seattle from August 21(st) to 25(th). Additionally, a new U.S. patent was issued earlier this year for Trovagene's non-invasive HPV assay, and the company continues to pursue its global partnering strategy to commercialize this novel technology.

Peter Hirth as Joins Trovagene's Scientific Advisory Board

Trovagene, Inc. announced that K. Peter Hirth, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Hirth is an industry leader and innovator with over 30 years of biotechnology and pharmaceutical discovery and development experience. A pioneer in the field of personalized medicine, Dr. Hirth led the organizations that developed both Sutent(R) and Zelboraf(R); two successful targeted cancer therapeutics.

Trovagene, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Trovagene, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's revenues were $56,000 against $49,000 a year ago. Loss from operations was $3,241,000 against $2,374,000 a year ago. Net loss was $1,077,000 against $5,270,000 a year ago. Net loss attributable to common stockholders was $1,079,000 or $0.06 basic and diluted per share against $5,279,000 or $0.34 basic and diluted per share a year ago. For the six months, the company's revenues were $166,000 against $168,000 a year ago. Loss from operations was $6,501,000 against $4,764,000 a year ago. Net loss was $4,267,000 against $6,381,000 a year ago. Net loss attributable to common stockholders was $4,278,000 or $0.23 basic and diluted per share against $6,396,000 or $0.41 basic and diluted per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TROV:US $4.06 USD -0.31

TROV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $26.29 USD -1.76
Genomic Health Inc $28.08 USD +0.05
Laboratory Corp of America Holdings $106.82 USD +0.67
Veracyte Inc $12.57 USD -0.05
View Industry Companies
 

Industry Analysis

TROV

Industry Average

Valuation TROV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 320.5x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 128.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TROVAGENE INC, please visit www.trovagene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.